GOP Lawmakers Rip FDA's Generic-Drug Labeling Overhaul

By Jeff Overley (January 23, 2014, 7:08 PM EST) -- Congressional Republicans on Wednesday sharply criticized the U.S. Food and Drug Administration's controversial plan to let generic-drug makers independently change their warning labels, saying they have "grave concerns" that the move would drive up costs and conflict with federal law.

In a lengthy letter, GOP lawmakers asserted that the FDA's proposed rule runs contrary to the Hatch-Waxman Act's so-called sameness requirement, which dictates that generic and brand-name drugs share identical labels.

Regulators have argued that the inability of generics makers to unilaterally revise labeling reduces their incentive to look for new risks. Also, because many brand-name products are pulled from the...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!